171.38 0.00 (0.00%)
After hours: 4:15PM EDT
Commodity Channel Index
|Bid||171.23 x 800|
|Ask||171.46 x 800|
|Day's Range||170.70 - 178.10|
|52 Week Range||95.58 - 179.38|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||34.43|
|Earnings Date||Jul 29, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||159.13|
Charles River Laboratories International (NYSE:CRL) shares have had a really impressive month, gaining 30%, after some...
Charles River Laboratories International, Inc. (NYSE:CRL), which is in the life sciences business, and is based in...
Charles River (CRL) delivered earnings and revenue surprises of 24.32% and 2.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horizon Kinetics LLC, a New York-based investment advisory firm founded in 1994, released its Q1 2020 Commentary – a copy of which is available for download here. It has over 70 employees and is led by Murray Stahl. Its investment strategy is long-term and contrarian oriented, and the fund usually holds a concentrated portfolio with original […]
Medpace is building a base and near a possible buy range ahead of its earnings report expected around Apr. 28.
Those holding Charles River Laboratories International (NYSE:CRL) shares must be pleased that the share price has...
Charles River today announced that it has entered into a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service.
To the annoyance of some shareholders, Charles River Laboratories International (NYSE:CRL) shares are down a...
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Charles River Laboratories appoints Nancy C. Andrews, M.D., Ph.D., Dean Emerita of Duke University’s School of Medicine, to its Board of Directors
James Foster became the CEO of Charles River Laboratories International, Inc. (NYSE:CRL) in 1992. This analysis aims...
It's been a good week for Charles River Laboratories International, Inc. (NYSE:CRL) shareholders, because the company...
In his second "Executive Decision" segment of Mad Money Tuesday evening, Jim Cramer checked in with Jim Foster, chairman, president and CEO of Charles River Laboratories Int'l. Charles River helps take a full year off of drug development time, saving billions of dollars. When asked about China, Foster said that Charles River has a research facility in China and is helping to educate the Chinese on the research-led model that is working so well in the U.S. Let's check and see how the charts of CRL are working.
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Charles River (CRL) delivered earnings and revenue surprises of 9.84% and 0.94%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?